Search

NICE drugs: an update on what’s good to go

Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...

Contemporary glaucoma therapy: spoilt for choice

The goal of glaucoma management is to prevent visual loss and disease progression in the patient’s lifetime through effective lowering of intraocular pressure (IOP), the primary modifiable risk factor in glaucoma. Sustained and consistent IOP reduction is key to halting...

My top five: Emerging alternatives to manage and treat nAMD

Wet (exudative or neovascular) age-related macular degeneration (AMD) is characterised by choroidal neovascularisation, in which new blood vessels from the choroid invade through Bruch’s membrane. These blood vessels proliferate beneath or through the retinal pigment epithelium (RPE), causing patients to...

Spotlight: The Community Eye Health Journal

In many low-income settings, where vision loss is greatest, eyecare is hampered by shortages in trained health workers. In sub-Saharan Africa, there are fewer than five ophthalmologists per million population, compared to over 70 per million in high-income countries. Eyecare...

OBITUARY: James Finbarr (Barry) Cullen

On the sad passing of Eye News’ first editor and long-term contributor JF (Barry) Cullen, his friend Hector Chawla takes a look at the life and career of this effervescent character and giant of the ophthalmology world. Barry Cullen was...

Evolving towards an interventional glaucoma mindset

Traditionally, a newly diagnosed glaucoma patient would be treated first with medical therapy. As the disease progressed or the initial intervention failed to adequately control intraocular pressure (IOP), clinicians would add more drops, selective laser trabeculoplasty (SLT), repeated SLT and...